Company Filing History:

14 out of 940

Fujisawa Pharmaceutical Company, Ltd.

Years Active: 1993-2009

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7557127 - HDAC inhibitor (2009-07-07),

2. 7465731 - HDAC inhibitor (2008-12-16),

3. 7135493 - HDAC inhibitor (2006-11-14),

4. 6407024 - Dielectric composition and ceramic capacitor made from the same (2002-06-18),

5. 6335302 - Dielectric composition and ceramic capacitor using the same (2002-01-01),

6. 6194396 - Benzimidazole compounds as bradykinin antagonists (2001-02-27),

7. 6169095 - Bradykinin antagonist quinolines (2001-01-02),

8. 6083961 - Benzimidazole compounds as bradykinin antagonists (2000-07-04),

9. 6083959 - Quinoline derivatives, processes for their preparation and their use as (2000-07-04),

10. 6008230 - Quinoline compounds as H.sup.+ -ATPases (1999-12-28),

11. 5994368 - Pyridopyrimidones, quinolines and fused N-heterocycles as bradykinin (1999-11-30),

12. 5922711 - 8-substituted quinazolines, quinoxalines and benzopyridazines (1999-07-13),

13. 5750699 - Method of preparing certain 3-halo-imidazopyridines (1998-05-12),

14. 5708173 - Heterocyclic compounds (1998-01-13),

15. 5574042 - Imidazo [1,2-a] pyridines and their pharmaceutical use (1996-11-12),

Title: Shigeki Satoh: A Pioneer in HDAC Inhibitor Innovations

Introduction: Shigeki Satoh, based in Tsukuba, Japan, is a distinguished inventor known for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 19 patents, Satoh focuses primarily on developing innovative compounds aimed at targeting various medical conditions. His latest research has led to breakthroughs in histone deacetylase (HDAC) inhibitors, showcasing his commitment to advancing therapeutic options.

Latest Patents: Among his recent inventions, Satoh's HDAC inhibitor patents are noteworthy. These patents involve compounds represented by the formula (I), which are designed to enhance the treatment options available for conditions influenced by histone deacetylases. His cutting-edge research continues to push the boundaries of pharmaceutical innovation.

Career Highlights: Shigeki Satoh has held prominent positions at notable organizations throughout his career. He has been associated with Fujisawa Pharmaceutical Company, Ltd. and Astellas Pharma GmbH, where he contributed his expertise to various projects. His dedication to innovation in the pharmaceutical field has established him as a respected figure among peers and researchers alike.

Collaborations: Collaboration has been a key aspect of Satoh's career, allowing him to work alongside talented individuals such as Teruo Kyoto Oku and Hiroshi Kayakiri. These partnerships have fostered a rich environment for creativity and research, culminating in valuable patents that impact the medical industry.

Conclusion: Shigeki Satoh’s work exemplifies the essence of innovation in pharmaceuticals, particularly through his advancements in HDAC inhibitors. With a solid foundation in research and collaboration, Satoh continues to be a driving force in the industry. His contributions not only enhance therapeutic options but also inspire future generations of inventors and researchers.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com